ReviewJournal of translational medicine2018
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Review in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 64 citations in OpenAlex.
- A framework for developing successful academic-industry partnerships for cardiovascular innovations.Heart rhythm O2 · 2026Review
- A scoping review of ethical aspects of public-private partnerships in digital health.NPJ digital medicine · 2025Article
- Undergraduate education as catalyst for public-private partnership in biotechnology.Nature biotechnology · 2025Article
- From Lab to Clinic: Effect of Academia-Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry.Clinical and translational science · 2025Article
- Open Innovation and Regulatory Challenges in New Modality Development: The Pivotal Role of Contract Development and Manufacturing Organisations in Advancing Antibody Drugs.Therapeutic innovation & regulatory science · 2025Article
- The Intersection of Business Innovation and Scientific Exploration to Address Early Mortality in People With Serious Mental Illness.JAMA psychiatry · 2023Article
- The Precompetitive Space for Drug or Vaccine Development: What Does It Look Like Now and What Could It Look Like in the Future?The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023Article
- Navigating the open innovation paradox: an integrative framework for adopting open innovation in pharmaceutical R&D in developing countries.The Journal of technology transfer · 2022Article
- Talent Flow Network, the Life Cycle of Firms, and Their Innovations.Frontiers in psychology · 2022Article
- Evolving scenario of big data and Artificial Intelligence (AI) in drug discovery.Molecular diversity · 2021Article
- Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.Pharmaceutical medicine · 2019Review
- External Knowledge Search and Innovation Performance in Iranian Biopharmaceutical Firms: The Mediating Role of Knowledge Integration Capability.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Historically, research and development (R&D) in the pharmaceutical sector has predominantly been an in-house activity. To enable investments for game changing late-stage assets and to enable better and less costly go/no-go decisions, most companies have employed a fail early paradigm through the implementation of clinical proof-of-concept organizations. To fuel their pipelines, some pioneers started to complement their internal R&D efforts through collaborations as early as the 1990s. In recent years, multiple extrinsic and intrinsic factors induced an opening for external sources of innovation and resulted in new models for open innovation, such as open sourcing, crowdsourcing, public-private partnerships, innovations centres, and the virtualization of R&D. Three factors seem to determine the breadth and depth regarding how companies approach external innovation: (1) the company's legacy, (2) the company's willingness and ability to take risks and (3) the company's need to control IP and competitors. In addition, these factors often constitute the major hurdles to effectively leveraging external opportunities and assets. Conscious and differential choices of the R&D and business models for different companies and different divisions in the same company seem to best allow a company to fully exploit the potential of both internal and external innovations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.